A 42-year-old female on alprazolam 1mg BID for panic attacks. Panic attacks have been in remission and the patient wants to taper off the medication.

Patient 2: A 42-year-old female on alprazolam 1mg BID for panic attacks. Panic attacks have been in remission and the patient wants to taper off the medication. But, every time she has attempted to do so in the past, she experienced withdrawal effects. She is wondering how to safely taper off the benzodiazepine medication without having withdrawal effects.

Patient 2

  • The patient reports withdrawal symptoms when previously tapering off the alprazolam. What symptoms are common withdrawal symptoms from this medication?
  • Provide the patient education of withdrawal symptoms that range from common and less serious to withdrawal symptoms that are a cause for concern and that should prompt patient should seek medical attention.
  • Given the patient’s history of having withdrawal effects from attempting to taper off alprazolam, what longer-acting benzodiazepine would you choose to convert the patient to?
  • What is the dose you would prescribe and how would you taper off the medication?

Patient 2

This case involves a 42-year-old female who is on Alprazolam for panic attacks and is seeking to withdraw but is concerned about the withdrawal effects. The common withdrawal symptoms associated with Alprazolam, taken together with other benzodiazepines, include anxiety, insomnia, tremors, nausea, sweating, and irritability (Ait-Daoud et al., 2019). It is essential to educate the patient about these possible symptoms to help her understand the expected outcome and possible signs that need immediate medical attention. The providers should also emphasize to patients that while experiencing withdrawal symptoms that may be uncomfortable, there is a possibility of adequately managing them. It is essential to educate the patient to understand that when a patient tapers off benzodiazepines, symptoms may continue over for some time (Reid Finlayson et al., 2022). It is also essential to educate the patient on the possible symptoms and appropriate responses that may be needed to assist in alleviating the withdrawal process.

GET A HUMAN-WRITTEN PAPER HERE

Based on the patient’s history of withdrawal, shifting to a longer-acting benzodiazepine may assist in having a smoother tapering process. Diazepam has been considered a preferred choice based on its long half-life and is available in various doses (Chang et al., 2024). A gradual tapering process will be essential to minimize the withdrawal symptoms. In this case, the 0.5 mg of Alprazolam is equivalence to 10 mg of Diazepam, and therefore, based on the patient’s Alprazolam daily dose, an initial conversion to 20 mg of Diazepam daily (10 mg twice daily) will be appropriate. The tapering off of the Alprazolam will be done gradually, with an estimated reduction of 5-10% every two weeks, and then the dosage will be adjusted based on her response. In their study, Ait-Daoud et al. (2018), Alprazolam’s recommended plan is for the taper not to extend 0.5 mg every three days. The pace of the tapering process will be adjusted based on the patient’s tolerance and symptoms.

 

References

Ait-Daoud, N., Hamby, A. S., Sharma, S., & Blevins, D. (2018). A review of alprazolam use, misuse, and withdrawal. Journal of addiction medicine, 12(1), 4-10. https://doi.org/10.1097/ADM.0000000000000350

Chang, Y., Xie, X., Liu, Y., Liu, M., & Zhang, H. (2024). Exploring clinical applications and long-term effectiveness of benzodiazepines: An integrated perspective on mechanisms, imaging, and personalized medicine. Biomedicine & Pharmacotherapy, p. 173, 116329. https://doi.org/10.1016/j.biopha.2024.116329

Edinoff, A. N., Nix, C. A., Hollier, J., Sagrera, C. E., Delacroix, B. M., Abubakar, T., … & Kaye, A. D. (2021). Benzodiazepines: uses dangers and clinical considerations. Neurology International, 13(4), 594-607. https://doi.org/10.3390/neurolint13040059

Reid Finlayson, A. J., Macoubrie, J., Huff, C., Foster, D. E., & Martin, P. R. (2022). Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey. Therapeutic advances in psychopharmacology, p. 12, 20451253221082386. https://doi.org/10.1177/20451253221082386